Skip to content

    Parkinson's Disease Health Center

    Font Size

    Gene Therapy for Parkinson's Nears

    First FDA-Approved Trial to Begin

    WebMD Health News

    Oct. 10, 2002 -- Researchers may soon find out if the hope lives up to the hype in using gene therapy to treat Parkinson's patients. Based on the findings of successful animal studies, the FDA has granted approval for the first tests of the experimental therapy in humans.

    The small, phase I clinical trial is set to begin in New York later this year. It will be the first gene therapy to be used in people with Parkinson's disease.

    Animal tests show the gene therapy stops the progression of the disease as well as reduces its symptoms. The findings appear in the Oct. 11 issue of the journal Science.

    People with Parkinson's disease experience a loss a substance called dopamine, which is used to transmit information within the brain. This drop in dopamine creates a disturbance in the part of the brain that controls movement. The region, known as the subthalamic nucleus (STN), becomes extremely overactive and creates the trembling and loss of muscular control found in Parkinson's patients.

    But studies have shown that when this area is silenced, patients experience a dramatic reduction in symptoms. The gene therapy uses a virus to deliver a specific gene to the STN, which "re-sets" the overactive cells and helps return brain function to normal.

    "Current surgical therapies for such patients attempt to interrupt this network abnormality by destroying overactive brain areas or placing DBS (deep brain stimulation) electrodes to quiet those areas," says researcher Michael G. Kaplitt, MD, director of stereotactic and functional neurosurgery at Weill Cornell Medical College, in a news release.

    "Both of these treatments, however, have certain limitations and side effects," says Kaplitt. "Our approach is based on a similar rationale, but we use gene therapy to adjust the chemical signaling of these brain areas to a more normal setting. This exploits the best parts of current therapy but makes it more powerful, less invasive, and potentially safer."

    In five tests on laboratory rats with simulated Parkinson's disease, researchers found that the gene therapy worked as anticipated to stop the progression of the disease. Rats that received the therapy retained more of their normal function and did not develop further signs of Parkinson's. The gene therapy has also successfully been tested in primates.

    Researchers say the virus used to deliver the gene has already been used in a variety of clinical gene therapy trials and has not been associated with any human disease.

    Today on WebMD

    Parkinsons disease illustration
    Causes, symptoms, and treatments.
    hands on walker
    How does the disease progress?
    man with serious expression
    8 common questions and answers.
    intelligence quotient illustration
    What are the advantages of DBS?
    Parkinsons Disease Medications
    Questions Doctor Parkinsons
    Eating Right
    Parkinsons Exercise
    daughter consoling depressed mother
    senior man's hands
    Parkinsons Daily